Ukena T E, Rosenkrantz H, Bessette R E, Esber H J
J Infect. 1987 Jan;14(1):39-42. doi: 10.1016/s0163-4453(87)90782-1.
Hepatitis B vaccine (Heptavax-B vaccine, Merck Sharp and Dohme) was given by injection into the buttock of 109 healthy workers in a community hospital according to the schedule of the U.S.A. Centers for Disease Control. In only 26% of those between 41 and 65 years of age was antibody to hepatitis B surface antigen found after the full course of vaccination whereas 74% of those aged 18-40 years had detectable antibody. We did not find any significant difference between the responses of males and females in either age group. The unusually poor response may be related to injections being given into the buttock rather than the deltoid region of the arm. We, therefore, recommend that injections of hepatitis B vaccine should be given into the deltoid muscle and that vaccinees should be tested after vaccination for evidence of immunity.
按照美国疾病控制中心的免疫程序，在一家社区医院给109名健康工作人员的臀部注射了乙肝疫苗（默克公司生产的Heptavax - B疫苗）。在41至65岁的人群中，完成全程疫苗接种后，仅26%的人检测出乙肝表面抗原抗体，而在18至40岁的人群中，74%的人检测出可检测到的抗体。我们未发现两个年龄组中男性和女性的反应有任何显著差异。这种异常低的反应可能与疫苗注射部位是臀部而非上臂三角肌有关。因此，我们建议乙肝疫苗应注射到三角肌，并且接种疫苗后应对接种者进行检测，以确定是否产生免疫。
